These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 20160034)

  • 1. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
    Kupperman E; Lee EC; Cao Y; Bannerman B; Fitzgerald M; Berger A; Yu J; Yang Y; Hales P; Bruzzese F; Liu J; Blank J; Garcia K; Tsu C; Dick L; Fleming P; Yu L; Manfredi M; Rolfe M; Bolen J
    Cancer Res; 2010 Mar; 70(5):1970-80. PubMed ID: 20160034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Lee EC; Fitzgerald M; Bannerman B; Donelan J; Bano K; Terkelsen J; Bradley DP; Subakan O; Silva MD; Liu R; Pickard M; Li Z; Tayber O; Li P; Hales P; Carsillo M; Neppalli VT; Berger AJ; Kupperman E; Manfredi M; Bolen JB; Van Ness B; Janz S
    Clin Cancer Res; 2011 Dec; 17(23):7313-23. PubMed ID: 21903769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
    Wang H; Yu Y; Jiang Z; Cao WM; Wang Z; Dou J; Zhao Y; Cui Y; Zhang H
    Sci Rep; 2016 May; 6():26456. PubMed ID: 27217076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
    Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
    Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
    Engür S; Dikmen M; Öztürk Y
    Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS
    J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
    [No Abstract]   [Full Text] [Related]  

  • 11. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
    Williamson MJ; Silva MD; Terkelsen J; Robertson R; Yu L; Xia C; Hatsis P; Bannerman B; Babcock T; Cao Y; Kupperman E
    Mol Cancer Ther; 2009 Dec; 8(12):3234-43. PubMed ID: 19934276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
    Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
    Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
    Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition in the treatment of cancer.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
    Williamson MJ; Blank JL; Bruzzese FJ; Cao Y; Daniels JS; Dick LR; Labutti J; Mazzola AM; Patil AD; Reimer CL; Solomon MS; Stirling M; Tian Y; Tsu CA; Weatherhead GS; Zhang JX; Rolfe M
    Mol Cancer Ther; 2006 Dec; 5(12):3052-61. PubMed ID: 17172407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
    Yu J; Tiwari S; Steiner P; Zhang L
    Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
    Demo SD; Kirk CJ; Aujay MA; Buchholz TJ; Dajee M; Ho MN; Jiang J; Laidig GJ; Lewis ER; Parlati F; Shenk KD; Smyth MS; Sun CM; Vallone MK; Woo TM; Molineaux CJ; Bennett MK
    Cancer Res; 2007 Jul; 67(13):6383-91. PubMed ID: 17616698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.